Finance

Lists
CERS:NASDAQ
Cerus Corp
2,30 US$
+0,88%
(+0,020) 1D
2,32 US$
+0,87% (+0,020)
Pre-market
Closed: 9 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CERS...
Open
2,31 US$
High
2,33 US$
Low
2,27 US$
Mkt. cap
463,51 მლნ.
Avg. vol.
1,65 მლნ.
Volume
367,00
52-wk high
3,47 US$
52-wk low
1,38 US$
EPS
-0,03 US$
Beta
1,83
Shares outstanding
201,52 მლნ.
No. of employees
268
Open
2,31 US$
High
2,33 US$
Low
2,27 US$
Mkt. cap
463,51 მლნ.
Avg. vol.
1,65 მლნ.
Volume
367,00
52-wk high
3,47 US$
52-wk low
1,38 US$
EPS
-0,03 US$
Beta
1,83
Shares outstanding
201,52 მლნ.
No. of employees
268
News stories
From web sources and news partners
Profile
Cerus Corporation is an American multinational biotechnology company headquartered in Concord, California that develops and provides a treatment system to pathogen-reduce human blood products for the healthcare industry. Wikipedia
About Cerus Corp
CEO-
Employees268
Foundedსექ 1991
HeadquartersConcord, კალიფორნია, ამერიკის შეერთებული შტატები
SectorMedical device
Websitecerus.com
Analyst ratings
Based on 2 analysts giving stock ratings to CERS in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for CERS in the last 3 months.
Highest
Current 2,30 US$
5,00 US$ (+117,39%)
Average
4,50 US$ (+95,65%)
Lowest
4,00 US$ (+73,91%)
Analyst
Recommendation
Action
Price target
Projected
Date
Josh Jennings
TD Cowen
Buy
Reiterated
5,00 US$
+117,4%
08/28/2026
Mark Massaro
BTIG
Buy
Reiterated
4,00 US$
+73,9%
08/14/2026
William Bonello
Craig-Hallum
Buy
Maintained
-
-
05/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
52,70 მლნ.
57,75 მლნ.
53,66 მლნ.
57,44 მლნ.
Cost of goods sold
24,56 მლნ.
28,00 მლნ.
25,77 მლნ.
27,91 მლნ.
Cost of revenue
24,56 მლნ.
28,00 მლნ.
25,77 მლნ.
27,91 მლნ.
Research and development expenses
15,82 მლნ.
16,39 მლნ.
14,53 მლნ.
14,39 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18,62 მლნ.
20,83 მლნ.
19,95 მლნ.
22,86 მლნ.
Operating expense
26,90 მლნ.
30,39 მლნ.
28,25 მლნ.
31,39 მლნ.
Total operating expenses
51,46 მლნ.
58,39 მლნ.
54,02 მლნ.
59,30 მლნ.
Operating income
1,24 მლნ.
-641,00 ათ.
-354,00 ათ.
-1,86 მლნ.
Other non operating income
976,00 ათ.
578,00 ათ.
520,00 ათ.
734,00 ათ.
EBT including unusual items
65,00 ათ.
-2,06 მლნ.
-1,56 მლნ.
-2,89 მლნ.
EBT excluding unusual items
65,00 ათ.
-2,08 მლნ.
-1,56 მლნ.
-2,89 მლნ.
Income tax expense
85,00 ათ.
119,00 ათ.
91,00 ათ.
95,00 ათ.
Effective tax rate
130,77%
-5,76%
-5,84%
-3,29%
Other operating expenses
-7,54 მლნ.
-6,83 მლნ.
-6,23 მლნ.
-5,86 მლნ.
Net income
-19,00 ათ.
-2,18 მლნ.
-1,64 მლნ.
-2,94 მლნ.
Net profit margin
-0,04%
-3,78%
-3,06%
-5,12%
Earnings per share
-
-0,01
-0,01
-0,01
Interest and investment income
-
-
-
-
Interest expense
-2,12 მლნ.
-1,96 მლნ.
-1,87 მლნ.
-1,71 მლნ.
Net interest expenses
-2,12 მლნ.
-1,96 მლნ.
-1,87 მლნ.
-1,71 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
1,62 მლნ.
-248,00 ათ.
93,00 ათ.
-1,40 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები